Over the past several years, there has been increasing concern that chemicals and pesticides found in the environment may mimic endogenous estrogens, potentially producing adverse effects in wildlife and human populations. Because estrogenicity is one of the primary concerns, a 90-day/one-generation reproduction study with 170-estradiol was designed to set dose levels for future multigenerational reproduction and combined chronic toxicity/oncogenicity studies. The purpose of these studies is to evaluate the significance of a range of responses as well as to provide benchmark data for a risk assessment for chemicals with estrogenlike activities. This 90-day/one-generation reproduction study was conducted in male and female Crl:CD BR rats using dietary concentrations of 0, 0.05, 2.5, 10, and 50 ppm 17/3-estradiol. Endpoints were chosen in order to evaluate both subchronic and reproductive toxicity. In addition, several mechanistic/biochemical endpoints were evaluated for their usefulness in follow-up studies. In the P, generation, dietary administration of 2.5,10, and 50 ppm 170-estradiol produced dose-dependent decreases in body weight, body weight gain, food consumption, and food efficiency. At 10 and 50 ppm 17^-estradiol, minimal to mild nonregenerative anemia, lymphopenia, decreased serum cholesterol (50 ppm only), and altered splenic lymphocyte subtypes were also observed in the P, generation. Additionally, at these concentrations, there were changes in the weights of several organs. Evidence of ovarian malfunction, characterized by reduced numbers of corpora lutea and large antral follicles, was observed at 2.5 ppm 17/3-estradiol and above. Other pathologic changes in males and females fed 10 and 50 ppm 17^-estradiol included centrilobular hepatocellular hypertrophy; diffuse hyperplasia of the pituitary gland; feminization of the male mammary glands; mammary gland hyperplasia in females; increased number of cystic follicles in the ovary; hypertrophy of the endometrium and endometrial glands in the uterus; 1 We gratefully acknowledge the partial funding of this project by the Chlorine Chemistry Council, 1300 Wilson Boulevard, Arlington, VA 22209.
Over the past several years, there has been increasing concern that chemicals and pesticides found in the environment may mimic endogenous estrogens, potentially producing adverse effects in wildlife and human populations. Because estrogenicity is one of the primary concerns, a 90-day/one-generation reproduction study with 170-estradiol was designed to set dose levels for future multigenerational reproduction and combined chronic toxicity/oncogenicity studies. The purpose of these studies is to evaluate the significance of a range of responses as well as to provide benchmark data for a risk assessment for chemicals with estrogenlike activities. This 90-day/one-generation reproduction study was conducted in male and female Crl:CD BR rats using dietary concentrations of 0, 0.05, 2.5, 10, and 50 ppm 17/3-estradiol. Endpoints were chosen in order to evaluate both subchronic and reproductive toxicity. In addition, several mechanistic/biochemical endpoints were evaluated for their usefulness in follow-up studies. In the P, generation, dietary administration of 2.5,10, and 50 ppm 170-estradiol produced dose-dependent decreases in body weight, body weight gain, food consumption, and food efficiency. At 10 and 50 ppm 17^-estradiol, minimal to mild nonregenerative anemia, lymphopenia, decreased serum cholesterol (50 ppm only), and altered splenic lymphocyte subtypes were also observed in the P, generation. Additionally, at these concentrations, there were changes in the weights of several organs. Evidence of ovarian malfunction, characterized by reduced numbers of corpora lutea and large antral follicles, was observed at 2.5 ppm 17/3-estradiol and above. Other pathologic changes in males and females fed 10 and 50 ppm 17^-estradiol included centrilobular hepatocellular hypertrophy; diffuse hyperplasia of the pituitary gland; feminization of the male mammary glands; mammary gland hyperplasia in females; increased number of cystic follicles in the ovary; hypertrophy of the endometrium and endometrial glands in the uterus; degeneration of seminiferous epithelium; and atrophy of the testes and the accessory sex glands. In the reproduction portion of this study, rats fed 10 or 50 ppm 17/3-estradiol did not produce litters. While there was no evidence that the 50 ppm treated rats mated, 33.3% of the rats fed 10 ppm mated but did not produce Utters. No effects on mating and fertility Indices were observed in rats fed 0.05 and 2.5 ppm 17/3-estradiol. Pup weights at birth were statistically decreased relative to control in the groups fed 0.05 and 2.5 ppm 17/3-estradiol. Weights of the rats in the 0.05 ppm group recovered by postnatal day 4 and remained similar to control throughout the remainder of the study. The mean gestation length of the 0.05 ppm group was slightly, albeit not statistically significantly, shorter (0.5 days) than that of the control group, which may have contributed to the decrease in birth weight of the 0.05 ppm group. In contrast, the weights of the F, generation rats fed 2.5 ppm 17/3-estradiol remained decreased relative to the control group throughout the study. Parental administration of 17/3-estradiol did not alter anogenital distance in male or female pups. The onset of sexual maturation, as measured by day of preputial separation in males and day of vaginal opening in females, was delayed in male rats fed 2.5 ppm (by 8.2 days) and was hastened in female rats fed 0.05 and 2.5 ppm (by 1.6 and 8.8 days, respectively). The age at vaginal opening ranged from 26 to 37, 26 to 35, and 21 to 25 days for rats fed 0, 0.05, and 2.5 ppm 170-estradiol, respectively. Hence, the range of age at vaginal opening was similar between the control and 0.05 ppm group. The organ weight and pathologic alterations observed in the adult F, generation rats were similar to those observed in the P, generation rats. However, in some instances the observed effects, such as histopathological findings in the female reproductive organs, were more severe in the F, generation than in the P, generation. Apparent differences in sensitivity between the P, and F, generations may be explained by the increased daily intake of 170-estradiol by the young F, generation rats, in utero exposure, or a combination of both. Dietary administration of 10 and 50 ppm 170-estradiol clearly exceeded a maximum tolerated dose. Future studies are needed to define the dose-response curve at dietary concentrations below 10 modulation of endogenous hormone function to produce cancer (mammary gland, testis, prostate), decrease sperm counts, and induce developmental abnormalities (urogenital and neurobehavioral defects) in humans (Sharpe and Skakkebaek, 1993; Safe, 1995; Colborn et ai, 1993; Crisp et ai, 1997) . Decreased reproductive success and developmental defects (masculinization/feminization) in wildlife have also been reported to be associated with industrial pollution (Ankley et ai, 1997; Colborn et ai, 1993) . Particular concern has arisen around the possibility that some of these compounds may act by mimicking the effects of estrogen (Colborn et al., 1996) .
The hypotheses linking dietary/environmental exposure to compounds with estrogen-like activity to increased risk of breast cancer, decreased sperm counts, increased incidence of testicular cancer, and increased incidence of male reproductive abnormalities require further research (Crisp et ai, 1997) . Safe (1995) has argued that dietary exposure to xenoestrogens derived from industrial chemicals or agricultural product residues in food is minimal compared to the daily intake of estrogen equivalents from naturally occurring bioflavonoids.
Due to the increasing concern that agricultural products and industrial chemicals may mimic endogenous estrogen, an exhaustive search of the scientific literature was conducted to determine the effects of 17/3-estradiol in rats. 17/3-Estradiol, a naturally occurring steroid hormone, is probably the most well-studied steroid hormone to date. While a plethora of data on the effects of estrogen in rats is available in the literature, much of these data were collected between 1920 and 1970, during the period when oral contraceptives were developed, often using study designs and rat strains different from those routinely used by toxicology laboratories today. It is known that considerable strain differences exist in the responses of rats to steroids, as well as differences in responses within strains, depending on the estrogen tested. A great deal of the data collected in the older studies concentrated on the tumorigenic effects of estrogens in combination with progestins or were conducted as short-term dosing studies. Comprehensive multigenerational reproduction or combined chronic toxicity/ oncogenicity studies on the effects of 17/3-estradiol are not available in the scientific literature. Such baseline information will provide a valuable case study with a natural and potent estrogen, which could be used as a benchmark to predict potentially adverse responses from exposure to less well-characterized chemicals with estrogen-like activity.
This report describes the results of dietary exposure of a 90-day/one-generation reproduction study conducted in male and female Crl:CD BR rats using dietary concentrations of 0, 0.05, 2.5, 10, and 50 ppm 17/3-estradiol. These dietary concentrations were selected based on the results of pilot studies as well as studies published by others. In addition to the traditional regulatory endpoints, evaluation of the immune system, ovarian morphometry, estrous cyclicity, hormonal measurements, Sertoli cell morphometry, and sperm analysis were conducted. This report presents the results of the 90-day/onegeneration reproduction study, ovarian and uterine morphometry, cell proliferation evaluation of uterus and mammary glands, and the immune system evaluation. Additional endpoints specific to either males (serum hormone concentrations, Sertoli cell morphometry and sperm analysis) or females (serum hormone concentrations and estrous cyclicity) are reported elsewhere Biegel et ai, 1998, respectively) .
MATERIALS AND METHODS
Material, diet preparation, and analyses. 17/}-Estradiol (98-100% pure) was purchased from Sigma Chemical Company (St. Louis, MO). An analytical grade standard, for use in the analysis of 17/}-estradiol in the diets, was purchased from Steraloids, Inc. (Wilton, NH). The stability of 17/3-estradiol in rodent chow was confirmed by analyses near the beginning and end of the study. Once during the 90-day study (approximately test day 45) and once during the reproduction study (approximately test day 45 for the F, generation), two samples per concentration were collected to verify the concentration of 17P-estradiol in the diets. These samples were stored frozen (-20°C) until analyzed. The concentration of 17/3-estradiol in the diets was determined by high-performance liquid chromatography with UV detection (HPLC-UV) for the 10 and 50 ppm diets and by HPLC with fluorescence detection for the 0.05 and 2.5 ppm diets. The analyses for the 10 and 50 ppm diets had extraction efficiencies of greater than 100%. This resulted from a diffuse matrix background adding to the UV detection response at the retention time of the 170-estradiol. This matrix response was subtracted from the analyte response by calculating a correction factor using spiked recovery samples as a basis.
17/3-Estradiol was added to PMI Feeds, Inc., Certified Rodent Diet 5002 (St. Louis, MO) and thoroughly mixed for approximately 6 min in a high-speed Hobart mixer to assure homogeneous distribution in the diet The initial diet analyses, conducted on test days -2 and 6, indicated that the 17/3-estradiol was not homogeneously distributed in the diets. In the preparation of subsequent diets, the mixing time of the diets was increased from 3 to 6 min and the 17/3-estradiol was dissolved in acetone (0.005% acetone based on amount of diet prepared). Analyses of the subsequent diets determined that the 17/3-estradiol was homogeneously distributed. During the test period, rats in each group were fed ad libitum a diet of PMI Feeds, Inc., Certified Rodent Diet 5002 that contained 0, 0.05, 2.5, 10, or 50 ppm 170-estradiol.
Animals and treatment.
Approximately 395 male and 520 female Crl:CD BR rats, at approximately 35 days of age, were purchased from Charles River Laboratories, Inc. (Raleigh, NC). The rats arrived with mean weights of 123.9 ± 18.03 g for males and 117.9 ± 11.28 g for females (mean ± SD.). Rats were quarantined for 6 days and evaluated for weight gain and any gross signs of disease or injury. The rats were released from quarantine by the laboratory veterinarian and selected for the study on the bases of body weights and freedom from clinical signs of disease or injury during the quarantine period. Rats were then divided by computerized, stratified randomization into male and female treatment groups so that there were no statistically significant differences among group body weight means within each sex. After assignment to treatment groups (n = 73 for males and n = 98 for females), each rat was assigned a unique six-digit number and designated for either subchronic evaluation (10/sex/treatment), cell proliferation (6 females/group/time point), or the reproduction subset (P, generation, 30/sex/treatment). Rats were also assigned to subsets for evaluation of other endpoints which are reported elsewhere Cook et al, 1998) . Animal rooms were maintained at a temperature of 23 ± I°C and a relative humidity of 50 ± 10%, and were artificially illuminated (fluorescent light) on a 12-h light/dark cycle (approximately 0600-1800 h). In a few instances, the temperature and humidity were outside the stated ranges, but die magnitude and duration were minimal and judged to be of no consequence. All rats were provided tap water and PMI Feeds, Inc., Certified Rodent Diet 5002 ad libitum. All rats were approximately 49 days of age on the day of study start.
All rats were housed individually in stainless-steel, wire-mesh cages during the quarantine, subchronic, and premating periods. During the mating period, rats were housed as breeding pairs in stainless-steel, wire-mesh cages. At the end of the cohabitation period, females without evidence of copulation were housed individually in polycarbonate pans. Presumed pregnant females were housed individually in stainless-steel, wire-mesh cages from gestation days 0 to 14 and in polycarbonate pans from gestation day 14 until the day of delivery. Females were housed with their litters in polycarbonate pans during the lactation period.
On postpartum day 21, offspring in the F, litters of each treatment level were selected (three weanlings/sex/litter) to continue on study. For groups without sufficient litters, additional pups were chosen from randomly selected litters within the group to achieve the required group size. Postpartum day 21 was designated as test day 0 for the F, generation rats.
All rats were weighed weekly during the subchronic phase of the study. P, females were weighed on days 0, 7, 14, and 21 of the gestation and lactation periods. Individual food consumption was determined weekly throughout the period, ending on test day 90 for the subchronic subset, test day 70 for the P, reproduction subset, and test day 77 for F, reproduction subset. Individual food consumption of pregnant P, females was recorded on gestation days 0, 7, and 14. From the body weight and individual daily food consumption data, food efficiency and mean daily intake of 17j3-estradiol (mg/kg/day) were calculated.
Cage-side examinations were conducted at least once daily throughout the study. At least once weekly rats were individually handled and carefully examined for abnormal behavior and/or appearance.
Clinical laboratory evaluations.
A clinical laboratory evaluation was conducted approximately 45 and 90 days after initiation of the study on the 10 male and female rats/group designated for the subchronic evaluation. At each sampling time, after an approximate 16-h fast, blood was taken from the orbital sinus of each rat while under light carbon dioxide anesthesia.
Hematology. The following hematologic parameters were measured or calculated: number of erythrocytes (RBC), leukocytes (WBC), and platelets (PLAT); hemoglobin concentration (Hb) and hematocrit (Hct); mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC); and relative numbers of neutrophils (Neut), band neutrophils (Band), lymphocytes (Lymph), atypical lymphocytes (Alym), monocytes (Mono), eosinophils (Eosin), basophils (Baso), and rcticulocytes (Retic). Absolute values for various types of leukocytes were calculated from the leukocytic data. Absolute values for reticulccytes (Absolute Retic) were calculated from the red blood cell data. Blood cell counts, hemoglobin concentration, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration were determined on a Serono Baker System 9000 hematology analyzer (Allentown, PA). Differential cell counts and reticulocyte counts were determined on a Hematrak automated differential system cell counter (King of Prussia, PA). Bone marrow smears were prepared at euthanization. The smears from animals in the control groups and the high-dose groups were qualitatively evaluated.
Clinical chemistry. In conjunction with hematological measurements, the following serum chemical parameters were measured or calculated: activities of alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) and concentrations of glucose (GLUCO), urea nitrogen (BUN), calcium (CALC), phosphate (PHOS), bilirubin (BILRN), cholesterol (CHOL), creatinine (CREAT), triglycerides (TRIG), total protein (TPROT), albumin (ALBMN), sodium (Na), potassium (K), and chloride (Cl). Clinical chemical analytes were measured on a Boehringer Mannheim/Hitachi 717 clinical chemistry analyzer (Indianapolis, IN) using Boehringer Mannheim reagents. Serum globulin (GLOBN) concentration was calculated from the total protein and albumin concentrations.
Urine analyses. The day prior to blood collection for hematological evaluation, an overnight (approximately 16-h) urine specimen was collected from each rat to measure volume (VOL), osmolality (OSMOL), urobilinogen (UROBL), and pH and to determine the presence of hemoglobin or occult blood (BLOOD), glucose, protein, bilirubin, and ketone (acetoacetic acid).
Osmolality was determined on a Precision System Multi-Osmette 2430 osmometer (Natick, MA). Urine biochemical constituents were measured with Ames Multistix urine chemistry dipsticks on a Clinitek 200 urine chemistry analyzer (Mishawaka, IN) . Urine appearance (color and transparency) was recorded and the sediment from each specimen was microscopically examined.
Pathological evaluation of the subchronic subset After approximately 90 days of continuous feeding, rats were euthanized by carbon dioxide anesthesia and exsanguination, necropsied, and examined for gross alterations. The order of euthanization was random among all treatment groups within a sex. The brain, heart, liver, spleen, pancreas, kidneys, pituitary glands, adrenal glands, testes, accessory sex glands (prostate, seminal vesicles, coagulating glands), epididymides, ovaries, and uterus were collected and weighed. In addition, organ weights relative to body weight were calculated. The following tissues were also collected in fixative for microscopic evaluation: skin, bone marrow (sternum and femur), thymus, aorta (thoracic), trachea, lungs, esophagus, stomach, small intestines, large intestines, bladder, thyroid gland, parathyroid glands, prostate, seminal vesicles, mammary glands (whole mount), cervix, vagina, eyes, and all gross lesions. Testes and epididymides were placed in Bouin's fixative. All other tissues were placed in formalin fixative. Tissues were further processed to slides and tissues from animals in the high-dose and control groups were examined microscopically. Tissues from other groups were examined as necessary to determine a no-observed-adverseeffect level in target organs.
Evaluation of splenic lymphocytes. At necropsy, spleens from P, rats (n = 10/gTOup) were weighed and bisected, and one-half was placed on ice in Hanks' balanced salt solution (HBSS) containing 1.0 M Hepes buffer and 7.5% NaHCO 3 (GIBCO Laboratories, Grand Island, NY). A single-cell suspension was then prepared from each spleen as described by Ladies and Loveless (1994) by first cutting the spleens into several pieces and then gently mashing the pieces between the frosted ends of two glass slides. The splenic cell suspension was placed into a conical tube and inverted several times, and debris allowed to settle for 5 min while the tube was kept on ice. Spleen cell numbers were determined using a Serono Baker 9000 hematology analyzer (Allentown, PA). RBC were lysed from splenic cell preparations of individual animals with the use of an ammonium chloride lysing reagent as described by Ladies and co-workers (1997) . Following RBC lysis, a second cell count was obtained for the immunofluorescent cell staining procedure.
Splenocytes were stained using the following mouse anti-rat monoclonal antibody (mAb) clones conjugated with fluorcscein isothiocyanate (FTTC): W3/25 (IgGl subclass), binding to most thymocytes, a helper T-lymphocyte (CD4 + ) subset, and macrophages (White et al., 1978) ; OX8 (IgGl), binding to CD8 + T-cells and NK cells (Brideau et al., 1980) ; and OX12 (IgG2a), which detects B-cells (Hunt and Fowler, 1981) . Splenocytes were also stained with the following mouse anti-rat mAb clones conjugated with phycoerythrin (PE): clone OX8 and clone G4.18 (IgG3), detecting CD3 + T-cells. Mouse IgGl (clone F8-11-13) conjugated with FITC or PE, mouse IgG2a (clone BZ-2) conjugated with FITC, and mouse IgG3 (clone J606) conjugated with PE were used as negative isotypic controls. All mAbs, except clones G4.18 and J606 (PharMingen, San Diego, CA), were obtained from Serotec Ltd. (Bicester, Oxon, UK). Each mAb was titrated to determine die optimal dilution to be used for cell staining. The dilutions of the isotypic controls were based on those used for the testing antibodies (Ab). Lymphocytes were labeled by a direct immunofluorescent staining procedure and immune cell staining data acquired and analyzed on a Becton-Dickinson (BD) FACScan flow cytometer as described by Ladies and co-workers (1997) . Plates were analyzed on a flow cytometer within 24-48 h.
One-generation reproduction subset Thirty rats in each treatment group were assigned to the one-generation reproduction subset with mating beginning on test day 70 of the subchronic study. All rats were fed the diet of their respective treatment group. During the mating period each female was continually housed on a 1:1 basis with a randomly selected male of the same dietary concentration level. Each female was housed in the male's cage for up to 14 days or until evidence of copulation, determined by observing intravaginal or extruded copulation plug (designated as day 0 of gestation). On the day Downloaded from https://academic.oup.com/toxsci/article-abstract/44/2/116/1611518 by guest on 10 April 2019 of confirmed copulation, the female was transferred back to individual cage housing.
On day 14 of gestation for mated females, or at the end of the cohabitation period for females without evidence of copulation, rats were transferred into polycarbonate pans and observed at least twice daily for signs of delivery and offspring. The day when delivery was complete was designated day 0 postpartum. On day 0 postpartum, live and dead pups in each litter were counted as soon as possible after delivery was completed. Live pups in each litter were weighed collectively by sex. Anogenital distance was microscopically determined using a dissecting microscope for each pup. On day 4 postpartum, litters were culled randomly to eight (four/sex when possible). Litters of eight offspring or less were not reduced. Litter counts and weights were determined prior to and after culling. On days 7 and 14 postpartum, pups in each litter were counted and weighed collectively by sex. On day 21 postpartum (weaning, test day 0 for the F, generation rats), pups in each litter were counted by sex and individual weights were recorded. At each examination period, offspring were individually handled and examined for abnormal behavior and appearance; any dead, missing, or abnormal pups were recorded. The four weanlings/sex/litter were randomly designated as pup 1, pup 2, pup 3, or pup 4. Weanlings designated as pups 1, 2, or 3 were selected to continue on study. Pup 4 was euthanized on approximately day 21 postpartum for a pathological examination (see below).
Developmental landmarks in the F, generation male and female rats were monitored on a daily basis for individual rats until criteria were achieved. The mean age at which each landmark was reached was compared across groups. Female rats were examined for vaginal patency beginning on postpartum day 21. Male rats were examined for preputial separation beginning on postpartum day 35.
Pathological evaluation of the reproduction subset After the completion of the mating period, P, males were euthanized by carbon dioxide anesthesia and exsanguination. At the end of the lactation period, P, females used to produce the F, generation were euthanized by carbon dioxide anesthesia and exsanguination. Culled pups were transferred to surrogate dams for use in other experiments (conducted at the University of Maryland and reported elsewhere). F, weanlings not selected to continue on study were euthanized by carbon dioxide anesthesia and exsanguination. One F, weanling/sex/litter (pup 4) underwent a gross pathological evaluation at postnatal day 21.
F, generation adult rats designated for histopathology were euthanized by carbon dioxide anesthesia and exsanguination and processed for pathological examination as described below. The brain, liver, pancreas (males only), pituitary glands, adrenal glands, testes, accessory sex glands, epididymides, ovaries, and uterus were collected and weighed, and organ weight/final body weight ratios were calculated. Additionally, the kidneys, spleen, vagina, cervix, and mammary glands were also collected. Testes and epididymides collected from male rats for histopathological evaluation were placed in Bouin's fixative. All other tissues were placed in formalin fixative. All tissues collected in the control and high-dose groups were evaluated microscopically.
Uterine and mammary gland cell proliferation and morphometric evaluation. Cell proliferation of the uterus and mammary gland was evaluated on six rats/group after approximately 7, 28, and 90 days of feeding for rats in the subchronic study and approximately on test day 77 for the F, reproduction study rats. The selected rats were injected with 5-bromo-2'-deoxyuridine (BrdU) (120 mg/mL, 5 mL/kg, via intraperitoneal injection) dissolved in a 0.5 N sodium bicarbonate buffer. After 3 h of BrdU exposure, the rats were euthanized by carbon dioxide anesthesia and exsanguination. The uterus and duodenum were collected and placed in Bouin's fixative. The skin pelt with mammary glands was removed in one piece from the perineum to the xiphoid process and laterally from behind each hind limb. The pelt was stapled flat, fur side down on doubled 3X5 cards, and placed in Bouin's fixative for 24 h. Tissues were then transferred to 70% ethanol. All tissues were then processed to blocks and stained immunohistochemically (Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA) for analysis of BrdU incorporation into DNA using an anti-BrdU antibody (Becton Dickinson, San Jose, CA). A labeling index (labeled cells /1000 cells counted) was determined for stromal and epithelial cells of the uterus and terminal end buds of the inguinal mammary gland. The duodenum was used as a positive control for staining of labeled cells. Additionally the uterine epithelial cell height was determined morphometrically using the OPTIMAS image analysis system (Optimas Corp., Bothell, WA) as previously described (O'Connor et al., 1996) . Briefly, in cross-sections of uterine hom, the basement membrane and luminal borders of multiple segments (total of approximately 2-4 mm) of the endometrial epithelium were outlined. Uterine height was determined based on the average distance between the luminal and basement membrane borders of the outlined uterine sections.
Ovarian morphometry. Ovarian morphometry was conducted on ovaries from subchronic study females at the 90-day time point and from F, generation females at the 77-day time point. Ovaries were placed in Kahle's fixative (4% formalin, 28% ethanol, and 0.34 N glacial acetic acid), Bouin's fixative, or neutral-buffered 4% formalin fixative for at least 24 h then transferred to 70% alcohol. After fixation, the tissues were dehydrated, embedded in Paraplast (VWR Scientific, Baltimore, MD), serially sectioned (7 )im), mounted on glass slides, and stained with Weigert's hematoxylin with picric acid and methylene blue as the counterstain.
Each section of every ovary was scanned at 40X magnification to locate all medium and large ovarian follicles. Sections throughout these follicles that contained the nucleolus of the oocyte were selected for closer analysis. Follicles were then examined under higher power and classified as healthy if they contained an intact oocyte, organized granulosa and thecal cell layers, and no pyknotic bodies. Follicles were classified as cystic if they were enlarged and thin-walled. Follicles were considered precystic if they contained abnormallyshaped (i.e., ruffled) and/or thinning granulosa cell layers.
A quantitative estimate of antral follicle number was obtained by counting large antral follicles as defined by an oocyte with a visible nucleolus, several layers of granulosa cells, thecal cell layers, and large antral spaces. To avoid counting follicles more than once, each large antral follicle was followed through several sections and only sections with a visible oocyte were used in the analysis. Both healthy follicles and those in the early stages of atresia were included in me overall count. The mean number of follicles was calculated from at least three different animals per group.
Statistical analyses. Body weights, body weight gains, food consumption, organ weights, gestation length, ovarian follicle number, cell proliferation indices, uterine epithelial cell height, clinical laboratory measurements, day of preputial separation, and day of vaginal opening were analyzed by a one-way analysis of variance (ANOVA). For ovarian follicle number, when statistical significance was achieved, Scheff^'s test was used in the post hoc analysis. For other parameters, when the test for differences among test group means (the value of the F test statistic) was significant, pairwise comparisons between test and control groups were made with the Dunnett's test. The Bartlett's test for homogeneity of variances was performed on the organ weight and clinical laboratory data and, when significant, was followed by nonparametric procedures. Incidences of clinical observations were evaluated by the Fisher's exact test with a Bonferroni correction and, when significant, the Cochran-Armitage test for trend.
Sequential trend tests were applied to die reproductive and flow cytometry data. If a significant dose response was detected, data for the high-dose group were excluded and the test was repeated until no statistically significant trend was detected. For flow cytometry data Jonckheere's test for trend was used. The mating index, fertility index, gestation index, and litter survival were analyzed using the Cochran-Armitage test for trend. For litter parameters, the litter mean was used as the experimental unit for statistical evaluation. Implantation site numbers, implantation efficiency, sex ratio, percent born alive, viability index, and lactation index were analyzed using Jonckheere's test. Where the data were tied and the standard large sample version of Jonckheere's test was not applicable, exact p values were calculated using permutation methodology.
Mean pup weights were analyzed using analysis of covariance (covariates: litter size, sex ratio) to determine the least square means, followed by sequen- 
RESULTS

90-Day Feeding Study
In-Life Parameters
The overall calculated mean daily intake of 17/3-estradiol can be found in Table 1 . Statistically significant decreases in the mean body weights (Fig. 1) , body weight gains, food consumption, and food efficiency were observed in male and female rats fed 2.5, 10, and 50 ppm 17/3-estradiol during the 90-day feeding phase of the study (Table 1 ). The only exception is food efficiency, which was not decreased in the females fed 2.5 ppm 17/3-estradiol. A dose-dependent increase in alopecia was observed in both male and female rats. The increased incidence was statistically significant in rats fed 10 (females only) and 50 ppm 17/3-estradiol (both sexes). The incidence of alopecia was 15, 10, 12, 19, and 30% (n = 73/group) in male rats and 14, 12, 18, 47, and 63% (n = 98/group) in female rats fed 0, 0.05, 2.5, 10, and 50 ppm, respectively.
Clinical Pathology
Hematology. Male (Table 2 ) and female (Table 3 ) rats in the 10 and 50 ppm treatment groups had mild nonregenerative anemia and leukopenia characterized by lymphopenia. At the 90-day sampling time, the mean values for the indicators of circulating erythrocyte mass (RBC, Hb, Hct) were 11 to 17% and 5 to 14% below the respective control group mean values in the 50 and 10 ppm groups, respectively. These decreases were statistically significant. Mildly decreased mean reticulocyte counts in some of these groups (not statistically significant) indicated that the anemia was nonregenerative. Statistically significant decreases in total leukocyte and lymphocyte counts were observed. Similar changes occurred at the 45-day sampling time point (data not shown). Collectively, these erythrocytic and leukocytic changes indicated that some degree of bone marrow toxicity had occurred. However, no bone marrow lesions or changes were detected during histopathologic or qualitative cytopathologic evaluations. No toxicologically important hematologic changes occurred at doses of 2.5 ppm or less.
Clinical chemistry. Male and female rats fed 50 ppm 17/3-estradiol had decreased cholesterol and male rats fed 10 ppm 17/3-estradiol had decreased triglyceride concentrations (Table  4) . Mean cholesterol concentrations were decreased in the 50 ppm male and female groups at the 90-day sampling time (statistically significant) and similar changes occurred at the 45-day sampling time (data not shown). In males, triglyceride concentrations exhibited an apparent biphasic response. The male 10 ppm group had decreased mean triglyceride concentration at both sampling times (statistically significant) and, in the 50 ppm group, mean triglyceride concentrations were not different from controls.
Urinalysis.
No toxicologically important urinalysis changes occurred in this study (data not shown).
•a ioo' Effect of 170-estradiol on body weights of male (A) and female (B) rats of the P, generation over the course of the 90-day feeding study. Mean body weights were decreased in both male and female rats fed 2.5, 10, and 50 ppm 170-estradiol.
Organ Weights and Anatomic Pathology
17/3-Estradiol-induced organ weight and pathologic changes in males and females are summarized in Tables 5-9 . Organ weight and/or histological changes were present in the liver, pituitary gland, adrenal glands, kidneys, spleen, skin, male and female mammary glands, and male and female reproductive organs only. Only primary target organ toxicity following subchronic exposure of rats to 17/$-estradiol is discussed.
Final body weight. Mean final body weights of male rats in the 90-day feeding phase of the study were 96, 81, 65, and 49% of control and in females were 96, 89, 79, and 69% of control in rats fed 0.05, 2.5, 10, and 50 ppm 17/3-estradiol, respectively (Table 5 ). The reductions in mean final body weight were statistically significant at 2.5, 10, and 50 ppm.
Liver. Liver weight relative to body weight was increased compared to controls in female rats in the 10 and 50 ppm groups (Table 7) . Since liver weights tend to decrease at least proportionately to decreased body weight (Chapin et al., 1993; Feron et al., 1973) , the presence of increased liver weights relative to body weight in these groups was considered to be related to 17/3-estradiol exposure. In addition, liver weight changes in females were associated with slight to mild centrilobular hepatocellular hypertrophy (Table 9) . Centrilobular hypertrophy was also present in males fed 10 ppm (Table 8) and above even though relative liver weights were not increased in these groups (Table 6 ).
Pituitary gland. Pituitary glands were weighed for groups of 15 male and 10 female rats from a subset of animals which will be used in a future neuroendocrinological evaluation. The absolute pituitary gland weight was increased in the 50 ppm males and females (statistically significant only in males) (Tables 6 and 7). The pituitary gland was grossly enlarged in 3 of 10 subchronic females in the 50 ppm group. Microscopically, diffuse hyperplasia of the pituitary gland was present in males fed 50 ppm 17/3-estradiol (Table 8 ) and in females fed 10 and 50 ppm 17/3-estradiol (Table 9) . Hyperplasia was primarily characterized by a slight, diffuse increase in cells of the pars distalis. By routine hematoxylin and eosin (HE) staining, the cytoplasm of these cells contained abundant pale granular eosinophilic secretory material rimmed by deeply basophilic cytoplasm. Since routine HE stains were employed, it was not possible to definitively identify the pituitary cell type(s) involved in this proliferative response.
Adrenal gland. Absolute adrenal weights were slightly increased in males fed 10 ppm and above and in females fed 50 ppm (Tables 6 and 7) . Although these changes were not statistically significant, these may be related to 17/3-estradiol exposure as increased adrenal weights and microscopic adrenal hypertrophy have been reported following exposure of rats to estrogenic compounds. In the current study, convincing microscopic evidence of adrenal cortical hypertrophy was not present. However, especially in animals of the 10 and 50 ppm groups, the normal cytoplasmic vacuolation of the zona fasiculata was decreased (with a resultant increase in eosinophilia). This finding may reflect depletion of glycogen or fat secondary to body weight decrements in these groups or it may indicate a slight response of the adrenal to 17/3-estradiol. Spleen, thymus, and kidney. Statistically significant decreases in absolute spleen weights were observed in rats fed 2.5 (males only) and 10 and 50 ppm 17/3-estradiol (both sexes) (Tables 6 and 7 ). In the spleen, the accumulation of yellowbrown granular pigment within macrophages, a normal finding in this strain of rat, was mildly increased compared to controls in 10 and 50 ppm males and females (equivocally in 10 ppm females) (Tables 8 and 9 ). No morphological differences were observed in the thymuses of rats of either sex. Increased pigment was also present in renal cortical tubular epithelium of 50 ppm males and females.
Relative and absolute numbers of splenic lymphocyte subtypes. Exposure of rats to 10 or 50 ppm 17/3-estradiol for 90 days resulted in a significant decrease in the absolute splenic cell numbers of both sexes (Table 10) . Absolute cell numbers are a measure of WBC counts. In male and female rats, exposure to 10 and 50 ppm 17j3-estradiol produced decreases in splenic WBC counts. At 50 ppm there was a decrease in the relative (%) numbers of female and male OX12+ (total Blymphocyte population) cells. In male and female rats, exposure to 10 and 50 ppm 17/3-estradiol decreased the absolute numbers of OX12+ and CD3+ (total T-lymphocyte population) cells (Table 10) . Additionally, exposure to 10 (females only) or 50 ppm 17^stradiol (both sexes) decreased the absolute numbers of W3/25+ (T-helper (T h ) cell population) and OX8+ (T-cytotoxic/suppressor (T cyt/sup ) cell population) cells in males (Table 10) .
Skin and mammary gland (males).
Slight to moderate atrophy of sebaceous glands was present in the skin of 10 and 50 ppm male rats fed 17/3-estradiol (Table 8 ). Since mammary glands of male rats were present in sections taken for evaluation of the skin, it was possible to evaluate this organ. In male rats fed 10 and 50 ppm, the typical lobuloalveolar structure of the mammary gland was changed to a tubuloalveolar morphology similar to that of the normal female mammary gland (Fig.  2) . Tubuloalveolar change was also present in the mammary gland of one of nine male rats in the 2.5 ppm group. This sometimes occurs in control male Crl:CD BR rats in this laboratory; therefore, it is uncertain whether this single occurrence represents a 17/3-estradiol-related finding.
Mammary gland (female rats). Increased incidence of hyperplasia, either multifocal or diffuse lobular, and/or dilatation of alveoli by secretory material were present in females fed 10 or 50 ppm of 17/3-estradiol (Table 9 ). Hyperplasia was slight to moderate and was characterized by increased numbers of alveoli with or without secretory dilatation. In females in the 50 ppm group, the increase in lobular size was more the result of secretory dilatation of acini as opposed to hyperplasia. However, at 10 ppm, lobular hyperplasia was more prominent and generally without a substantial secretory component. The causality of mammary gland hyperplasia in one female in the 2.5 ppm group was not determined since this finding may be seen in control rats of this strain and age. A mammary gland adenocarcinoma was found in one female in the 50 ppm group.
There were no statistically significant increases in cell pro- Pituitary weights are from a neuroendocrine subset of animals (n = 15), not the subchronic subset from which other organ weights were collected. The mean final body weights did not differ between the two subsets.
"Mean ± SD, n = 10/group. c Number in parentheses represents percentage of control. * Significantly different from control using Dunnett's test (p £ 0.05). ** Significantly different from control using Dunn's test (p £ 0.05).
liferation of terminal end buds in the mammary gland at any of the concentrations tested (Table 11) . Statistically significant decreases were found in the 2.5 and 10 ppm groups after 1 week, but these were not associated with a dose response and did not occur at other time points. Thus, these were possibly spurious findings.
Testes and epididymides. Absolute testes weights were decreased (Table 6) , and testes were grossly small in 2/10 and 9/10 males fed 10 or 50 ppm of 17/3-estradiol, respectively. Similar incidences of grossly small epididymides were also present in these groups. Microscopically, slight to moderate diffuse atrophy of interstitial cells was present in both the 10 and the 50 ppm groups (Table 8) . Atrophied interstitial cells had scant cytoplasm and loss or reduction of normal cytoplasmic eosinophilia . In the 50 ppm group, changes in seminiferous tubules were characterized by marked degeneration and loss of germ cells, most notably elongate spermatids. As a result, the adluminal layer of germ cells was typically composed of round spermatids or spermatocytes. At 10 ppm, changes in the seminiferous tubules were generally very slight and were most commonly characterized by degeneration of individual spermatocytes and spermatids and retention of spermatids in the basement membrane of the tubules. Correlative changes in the epididymides were characterized by oligospermia or aspermia, the presence of germ cell debris in the lumen of tubules, and atrophy of epididymal tubules.
Accessory sex glands. The weight of the accessory sex gland unit was decreased in males fed 2.5 ppm and greater (Table 6 ). The accessory sex glands were grossly atrophied in males fed 10 or 50 ppm 17/3-estradiol. These gross changes were generally correlative to microscopic atrophy of the prostate and seminal vesicles, components of the accessory sex glands (Table 8) .
Ovaries. Ovarian weights were decreased (Table 7) and microscopic evidence of ovarian malfunction (atrophy and decreased corpora lutea) ( Table 9 ) was present in females fed 2.5 ppm and above. Microscopically, the severity of atrophy was dose related and was characterized by decrease or absence of corpora lutea and increased foUicular atresia (including cystic atresia). Qualitatively there was also an apparent decrease in the number of most of the follicular developmental stages, yet the primordial follicle pool appeared healthy (Fig. 3) . Using morphometric analysis, the number of large antral follicles was similar in ovaries from controls and animals treated with 0.05 and 2.5 ppm 17/3-estradiol (Fig. 4) . Ovaries from animals treated with 10 and 50 ppm 17/3-estradiol often contained large cysts and significantly fewer antral follicles than the control animals.
Uterus. Uterine weights were increased in the 10 and 50 ppm groups, although not in a dose-related manner (Table 7) . The absence of a dose response may be the result of mitigation of the estrogenic effects on the uterus by the more severe body weight effects in the 50 ppm group. Grossly, fluid was present in the uterine lumen in 1/10 and 3/10 females in the 10 and 50 ppm groups, respectively. Microscopically, uterine changes were primarily characterized by slight hypertrophy of the epithelium of the endometrium and endometrial glands at 10 ppm and above (Table 9 ). The diagnosis of hypertrophy was used to represent an increase in epithelial cell height greater than that typically seen in the estrual or proestrual uterus. Low incidences of slight focal squamous metaplasia were also present in the endometrium and endometrial glands of 50 ppm females.
There were no statistically significant changes in labeling indices of uterine stromal cells at any of the concentrations tested (Table 12 ). The labeling indices of uterine epithelial cells were significantly decreased in the 10 and 50 ppm groups after 28-days and, although not statistically significant, remained decreased in the 50 ppm group after 90 days. The height of the uterine epithelium was significantly increased in 50 ppm females following 28 days on test and in the 10 and 50 ppm groups after 90 days on test (Table 12) .
Vagina. Incidences of estrus based on vaginal histology (Yuan, 1991) were increased in females fed 10 ppm 17/3-estradiol and greater (Table 9 ). In some treated females, the histology of the vaginal mucosa resembled that of a proestrous mucosa except that the striatum granulosum (and stratum cornium) were absent or poorly developed, and the stratum mucinification was thickened (Fig. 5 ). This change is usually correlated with proestrus based on vaginal cytology (Biegel el al., 1998) and, thus, was diagnosed as proestrus with hypertrophy. Note. NE, not examined. Number examined is underlined.
One-Generation Reproduction Study: P, and F t Preweaning Evaluations
Reproductive Indices
Reproductive indices were affected in rats fed 10 and 50 ppm 17/3-estradiol (Table 13 ). There was no evidence that mating occurred in the 50 ppm group, based on the absence of copulation plugs. In rats fed 10 ppm 17/3-estradiol, the mating index (number copulated/number cohoused) was decreased to 33.3%; however, no litters were subsequently produced. There was no effect on mating or fertility in rats fed 0.05 or 2.5 ppm 17/3-estradiol.
P, Gestation and Lactation In-Life Parameters
During the gestation and lactation phases of the study, statistically significant decreases in mean body weights were observed in rats fed 2.5 ppm 17/3-estradiol (Fig. 6) . Body weight gains and food consumption (not measured during lactation) were also decreased in rats fed 2.5 ppm 17/3-estradiol (Table 14) .
F, Preweaning Evaluations
There were decreased numbers of pups/litter born, number of pups born alive, and number of pups alive on day 4 (pre-and postculling) in rats whose parents were fed 2.5 ppm 17/3-estradiol (Table 15 ). There were also decreased weights in the F| generation pups in the 2.5 ppm group during the lactation periods, while the decrease in pup weight in the 0.05 ppm group was present only at birth (Table 16 ). There were no statistically significant differences in the anogenital distance in the treatment groups. There was an increase in the time to preputial separation in male pups in the 2.5 ppm group and a decrease in the time to vaginal patency in female pups in the 0.05 and 2.5 ppm groups (Table 17) . Forty-three percent (24/ 56) of the female pups in the 2.5 ppm group were vaginally patent on the day of weaning.
One-Generation Reproduction Study: Fj Postweaning Evaluations
In-Life Parameters
The overall calculated mean daily intake of 17/3-estradiol for F, rats can be found in Table 18 . During the F, 77-day feeding phase of the study, statistically significant decreases in mean body weights were observed in the male and female 2.5 ppm groups (Fig. 7) . Body weight gains, food consumption (males only), and food efficiency (females only) were also decreased in male and female rats fed 2.5 ppm 17/3-estradiol (Table 18) . No clinical signs of toxicity were observed over the course of the study. " Cell counts were conducted on approximately one-half of each spleen. * Mean ± SE, n = 7 to 10/group. One replicate of each cell marker was run for each animal/group following the lysis of red blood cells with an ammonium chloride solution.
c Number in parentheses represents percentage of control. d ^helper cells were quantitated using immunofluorescent staining with clone W3/25 (anti-CD4) and clone G4.18 (anti-CD3). '^c^aoimpimiKK c^'s were quantitated using immunofluorescent staining with clone 0X8 (anti-CD8) and clone 04.18 (anti-CD3).
•^Total B-cells were quantitated using clone 0X12 (anti-rat kappa light chain). * Total T-cells were quantitated using clone G4.18 (anti-CD3). * Significantly different from control using Jonckheere's Trend Test (p £ 0.05).
Organ Weights and Anatomic Pathology
17/3-Estradiol-induced organ weight changes for males and females are summarized in Tables 19-21 . Microscopic changes for females are summarized in Table 22 . There were no observable microscopic lesions in the F, male rats. Organ weight and/or histological changes were present in the liver, pituitary gland, adrenal glands, kidneys, spleen, female mammary glands, and male and female reproductive organs. The alterations in the kidney and spleen are considered to be secondary to body weight decreases and not primary effects of exposure to 17/3-estradiol; therefore, they are not discussed.
Final body weight. During the 77-day feeding phase, mean final body weights of F, males were 94 and 72% of control in the 0.05 and 2.5 ppm 17/3-estradiol groups, respectively (Table  19 ). The mean final body weights of F, females were 99 and 80% of control in the 0.05 and 2.5 ppm 17/3-estradiol groups, respectively (Table 19 ). The reductions in mean final body weight were statistically significant at 2.5 ppm in both sexes.
Liver. Liver weight (relative to body weight) was increased compared to controls in F, females in the 2.5 ppm group (Table 21) . Although not associated with definitive histological changes, this increase in relative liver weight, despite concomitant body weight decrements, is likely the result of exposure to 17/3-estradiol.
Pituitary gland. Pituitary weights were increased in F, male and female rats fed 2.5 ppm (Tables 20 and 21 ). In FIG. 2 . Mammary gland from a male control rat (A) and a male rat fed 10 ppm 17/3-estradiol (B). The control mammary gland has a lobuloalveolar architecture without prominent ducts. The mammary gland from the treated rat has small tubuloalveolar lobules similar to the normal female gland. HE, scale bar, 100 \txa.
females, these changes were associated with microscopically Adrenal gland. Statistically significant increases in adrenal detectable diffuse pituitary hyperplasia similar to that noted for weights were present in the 2.5 ppm F, males (Table 20) . animals in the subchronic study (Table 22) .
However, increased adrenal gland weight (relative to body weight) was likely secondary to body weight effects (Scharer, 1977) . There were no definitive microscopic changes in the adrenal glands in either males or females. However, as noted for the subchronic study, equivocal tinctorial changes in some adrenals may be reflective of an early response of cortical cells to stimulation.
Mammary gland (females).
Increased incidences of hyperplasia, either multifocal or diffuse lobular, and/or dilatation of acini by secretory material were present in Fj females fed 2.5 ppm 17/3-estradiol (Table 22 ). Hyperplasia was characterized by increased profiles of alveoli. Lobular hyperplasia in the 2.5 ppm F] female group was more typically associated with slight to mild secretory dilatation of alveoli. There were no alterations in cell proliferation of the terminal end buds of the mammary glands in the F, females (Table 11) .
Testes and epididymides. In 2.5 ppm F, males, the absolute testicular and epididymal weights were decreased compared to controls (Table 20) .
Accessory sex glands. The absolute accessory sex glands weight was decreased in the 2.5 ppm F, group (Table 20) . There were no gross or microscopic findings in the accessory sex glands of F, males although equivocal secretory depletion was present in some F, males fed 2.5 ppm 17/3-estradiol.
Ovary. There was a statistically significant decrease in absolute and an increase in relative (to body weight) ovarian weights an in F, females fed 2.5 ppm 17/3-estradiol (Table 21) . Microscopic changes similar to those noted in the subchronic study were present in the 2.5 ppm F, females (Table 22) .
Using morphometric analysis, the number of follicles was similar in ovaries from the F, generation control and animals treated with 0.05 ppm 17/3-estradiol (Fig. 4) . However, the number of large antral follicles was significantly reduced in animals treated with 2.5 ppm 17/3-estradiol. There were no significant differences in follicle number between P, and F, rats fed 0 or 0.05 ppm 17/3-estradiol (Fig. 4) . In contrast, the number of antral follicles in rats fed 2.5 ppm 17/3-estradiol was significantly lower in the F! generation compared to the P, generation.
Uterus. There were no statistically significant changes in uterine weight in the F, generation females (Table 21) . However, microscopic changes similar to those observed in the subchronic study were observed in the 2.5 ppm F, females (Table 22 ). There were no statistically significant changes in height of the uterine epithelium in F, females (Table 12) .
Vagina. Instances of estrus by vaginal histology were increased in Fj females fed 2.5 ppm (Table 22) . Thickening of the mucosa of the proestrual vagina, noted in the subchronic study, was also seen in 2.5 ppm F, females.
DISCUSSION
Over the past several years there has been growing concern around some in vitro evidence that suggests some commodity chemicals, such as nonylphenol and bisphenol A, have estrogenlike activity (Soto et al, 1991; Krishnan et al., 1993; Colbom et al., 19%; Dodds and Lawson, 1936) . As a result, Congress passed legislation mandating the U.S. EPA to implement screening procedures for endocrine active compounds (EACs) before 1999. However, there is an absence of long-term dietary exposure data with a pure estrogen receptor agonist against which other compounds of unknown activity would be compared, to assess potential estrogen-like activity. The current 90-day/one-generan'on reproduction study with 17/3-estradiol was designed to set dietary concentrations for a multigeneration reproduction study and a combined chronic toxicity/oncogenicity study. These studies will provide benchmark data to which unknown chemicals can be compared in order to help distinguish between adaptive and adverse responses. This is the first study to investigate the dietary dose response of 17/3-estradiol using a regulatory/standard toxicology study design.
Most of the observations reported in the 90-day feeding study are consistent with those reported by others in short-HG. 3. Ovary from a control rat (A) and a rat fed 50 ppm 170-estradiol (B). The ovary from the treated rat has an absence of corpora lutea, decreased numbers of normally developing follicles, and increased numbers of thin-walled cystic follicles. However, primordial follicles are present (inset, arrows). HE, scale bar, 250 /im. term, less comprehensive, or oral exposure studies using estrogen and progestin combinations (Kuhnz and Putz, 1989; Attia and Zayed, 1989; Gibson et al., 1967; Schardein et al., 1970 ; reviewed by Heywood and Wadsworth, 1980) . The effects of estrogens on the growth and body weight of rodents are well documented. Both synthetic and natural estrogens FIG. 4 . Effect of 17p-estradiol on the number of ovarian large antral follicles in P, (A) and F, (B) generation rats. Decreases in the number of large antral follicles were observed through morphometric analysis of ovarian serial sections. Statistically significant decreases were observed in P, rats fed 10 and 50 ppm 17/3-estradiol and in F, rats fed 2.5 ppm 17^-estradiol. *Significantly different from control using Dunnett's test (p S 0.05).
decrease the growth rate in rats and mice (Heywood and Wadsworth, 1980; Hart, 1990) . The effects of estrogens on the growth and body weight of rodents involve decreases in food and water intake (Finkelstein, 1986; Hart, 1988) , adiposity (Wade et al., 1985; Wade and Gray, 1979) , and an adjustment in regulated body weight (Coling and Herberg, 1982) . In decreasing appetite in the rat, estrogens appear to act centrally at the hypothalamus. The dose-dependent growth retardation, decreases in food consumption, and alopecia observed in the current study have been reported in long-term studies with most estrogens. However, in a study conducted by Ferrando and Valette (1975) , administration of 17/3-estradiol (at 0.12 and 0.24 ppm) in the diet for 90-days to Wistar rats did not produce any effects on body weight or food consumption, while diethylstilbesterol (DES) administration (0.06 and 0.12 ppm) produced the classical decreases in body weight and food consumption. In the current study, these endpoints were affected at dietary concentrations of 2.5, 10, and 50 ppm (0.14/ 0.17, 0.53/0.69, and 3.2/4.1 mg/kg/day for male/female rats, respectively), but not 0.05 ppm 17/3-estradiol. The changes in cholesterol and triglyceride concentrations at 10 and 50 ppm 17/3-estradiol indicated altered lipid metabolism and they may have been associated with the marked body weight effects. The reductions in body weight and food consumption were also observed in females throughout gestation and lactation as well as in the F, generation rats fed 2.5 ppm 17/3-estradiol. Note, nd, not determined. -, no litters were produced. " Mean ± SD, n = 6 for all groups and time points.
• Significantly different from control using Dunnett's test (p • ; 0.05).
The body weight and nutritional effects produced following exposure to estrogenic compounds, particular the more severe effects seen at high doses, can potentially complicate the interpretation of organ weight and pathology findings (Heywood and Wadsworth, 1980) . In cases of chronic body weight decrements, weight changes in most organs tend to follow a pattern characterized by decreased or unchanged absolute organ weights and increased or unchanged relative (to body weight) organ weight ratios (Feron et al, 1973; Oishi et al., 1979; SchSrer, 1977) . Such a pattern was noted for a number of organs in rats fed high dietary concentrations of 17/3-estradiol. The significance of organ weight changes was interpreted based on the pattern of change and the presence or absence of correlative microscopic changes. For example, depending on the severity and duration, body weight decrements alone may be associated with atrophy of reproductive organs in both male and female rats (Feron et al, 1973; Grewal et al., 1971; Yuan, 1991) . Moreover, the effects on reproductive organ weights in the current study can be compared with those reported in association with comparable body weight decrements in diet restriction studies (Feron et al, 1973; Grewal et al, 1971; Chapin et al, 1993) . For example, in the current study, absolute testis weights were decreased to 25% of controls and testes were atrophied both grossly and microscopically in the 50 ppm 17/3-estradiol group. The final body weight in that group was 51% of control. At similar body weight decrements in a diet restriction study in Sprague-Dawley rats (Grewal et al, 1971) , absolute testes weight was only decreased to 75% of controls (testes were not examined microscopically in that study), suggesting a compound-related effect was observed in male rats fed 50 ppm 17/3-estradiol. Also, in the 10 ppm 17/}-estradiol male group from the current study, absolute testes weights were decreased to 84% of controls and testicular degeneration, albeit slight, was present microscopically. Final body weights in this group were 68% of control. However, Chapin and co-workers (1993) reported no effects on testicular weight in Sprague-Dawley rats feed restricted to 70% of ad libitum control body weight for up to 17 weeks.
While decreases in ovarian weight may occur in association with body weight loss, comparisons between 17/3-estradiol-induced ovarian atrophy and ovarian effects associated with feed-restriction-induced body weight effects provide additional observations indicating weight loss alone is insufficient to produce the observed ovarian weight decreases (Chapin et al, 1993; Feron et al, 1973) . In females fed 10 ppm 17/3-estradiol in the current study, body weight and absolute ovarian weight were decreased to 79 and 57% of control, respectively. In contrast, no effects on ovarian weight were seen in Sprague-Dawley rats feed restricted to 80% of ad libitum control body weight for up to 17 weeks (Chapin et al, 1993 ). These comparisons demonstrate that most of the changes in reproductive organs following exposure to 17/3-estradiol are not simply secondary to body weight effects.
One likely exception to the above conclusion is the effect on accessory sex gland weights from rats fed 2.5 ppm 17/3- estradiol in the subchronic study and adult F, rats from the organ structures. This effect is reported to be due to decreased reproduction study. Decreased body weight gain secondary to serum testosterone (Chapin et al., 1993) which was also seen in diet restriction is known to reduce the weight of accessory sex this study and reported elsewhere (Cook et al, 1997) . How- ever, in male rats fed 10 or 50 ppm 17/3-estradiol, the magnitude of weight changes in the accessory sex gland unit exceeded that reported (for prostate or seminal vesicles) in feed restriction studies where body weight changes of similar magnitudes were produced. Therefore, effects on the accessory sex gland unit in rats fed 10 and 50 ppm did not occur merely secondary to body weight changes. At 2.5 ppm 17/3-estradiol, the mean absolute accessory sex organ weight was decreased (statistically significant in the F, generation). However, the magnitude of change in the weight of the accessory sex organ was similar to that reported in the prostate and seminal vesicles, at comparable body weight decrements, in previous feed restriction studies (Chapin et al, 1993; Oishi et al., 1979) . Also, there was no gross atrophy of the accessory sex gland in the 2.5 ppm groups as was seen at higher concentrations of 17/3-estradiol. Therefore, primary effects on accessory sex glands, if any, at 2.5 ppm of 17/3-estradiol cannot be differentiated from effects occurring secondary to body weight changes.
The tubuloalveolar change noted in the mammary gland of male rats fed 10 or 50 ppm 17j3-estradiol has not been widely reported in other studies with estrogenic compounds. Schardein and co-workers (1980) reported enhanced secretory activity and cystic ductal dilatation in the mammary gland of male Sprague-Dawley rats fed ethinylestradiol at dietary concentrations of 0.08 mg/kg for 2 years. Few reports are available on the normal morphology and response to xenobiotics of the mammary gland in male rats. The most thorough treatise on this subject was published by Cardy (1991) . He noted that a striking sexual dimorphism exists in the normal mammary gland of rats. The normal mammary gland of the sexually mature female can be described as a tubuloalveolar structure composed of branching tubular ducts, terminal end buds, and clusters of patent alveoli. In contrast, the normal male mammary gland is a lobuloalveolar structure composed of cells containing foamy eosinophilic cytoplasm arranged in prominent alveoli but with little obvious tubular or duct orientation ( Fig. 2A) . In the present 90-day study, the mammary glands of 10 and 50 ppm male rats were morphologically similar to the normal female mammary gland (Fig. 2B) . Similar changes were observed in the mammary gland of male rats following exposure to a dopamine blocking agent (Cardy, 1991) . Dopamine antagonists produce increased levels of serum prolactin by blocking the inhibitory effect of dopamine on pituitary release of prolactin. Therefore, increases in serum prolactin might be one of several possible factors responsible for the feminization of the male mammary gland following exposure to dopamine blocking agents. The relative contributions of the elevated serum prolactin and estradiol concentrations on the mammary gland changes noted in male rats in the current study are unknown, although in male rats treated identically to the current study, statistically significant increases in serum estradiol and prolactin concentrations were observed in rats fed 2.5, 10, and 50 ppm 17/3-estradiol .
An important aspect of the present study is that it provides some insights on the importance of stages of development on the effects of 17/3-estradiol. Rats were exposed in utero through early adulthood (adult Fj generation from the reproduction study), as well as beginning just prior to puberty for 13 weeks (subchronic study). One of the more notable findings in the current study was the increased severity of some 17/3-estradiol-induced microscopic changes in the 2.5 ppm F! generation rats compared to 2.5 ppm rats in the subchronic study. This was especially prominent in female reproductive organs. Evidence of ovarian malfunction, though present at 2.5 ppm in both generations, was distinctly more prominent in the F, 6.8 (6.47) ± 0.84* 10.6 (9.78) ± 1.98* 10.6 (9.86) ± 1.98* 15.6 (14.89) ±2.54* 29.1 (28.46) ± 3.73* 47.7 (46.69) ± 5.32* " Statistics were conducted on the combined male and females mean pup weights only. b The number in parentheses is the least square mean generated from analysis of covariance where the covanants were sex ratio and litter size. c Mean ± SD. * Significantly different from control using analysis of covariance (covariates: litter size, sex ratio) to determine least square means, followed by Jonckheere's trend test (p £ 0.05).
generation. Indeed in most 2.5 ppm F, females, the severity of ovarian atrophy more resembled that observed at 10 or 50 ppm in the older generation animals of the subchronic study. Similar differences between generations were noted in the uterus and female mammary glands. There were no definitive 17/3-estradiol-related changes in the uterus of 2.5 ppm P, females. However, squamous metaplasia of the uterus, though never severe, was a more frequent finding in 2.5 ppm F, females compared to the Pj females from the subchronic study fed 10 or 50 ppm 17/3-estradiol. Mammary gland hyperplasia was present in only one female in the 2.5 ppm group in the subchronic study. In 2.5 ppm Fj females from the reproduction study, hyperplasia was present in 13 of 20 animals and was usually associated with evidence of secretory activity, a finding common only at 50 ppm in the subchronic study. Kelce and Gray (1996) indicate that the fetus or progeny may be substantially more susceptible to insults by EACs than are adults. However, this was not clearly demonstrated in the current study. While some effects, such as the histopathology findings of the female reproductive organs, were more severe in the F, than in the Pj generation rats fed 2.5 ppm 17/3-estradiol, not all of the findings were so clear. For example, the significance of the decrease in absolute testicular weight of F, rats fed 2.5 ppm (91% of control) is uncertain. This change was small and was not associated with correlative microscopic findings. Additionally, in rats treated identically to those in the current study, Cook and co-workers (1998) did not observe a decrease in testis weight supporting the conclusion that the decrease in the current study is an equivocal finding. However, minimal alterations were observed in testicular spermatid number (increased), absolute epididymal weight (decreased), and epididymal sperm number (decreased) . The increased sensitivity in some of the responses of the F, rats compared to the P, rats may actually be a dose-response phenomenon rather than a generational effect. The mean daily intake of the F, generation rats was considerably higher than the P, rats in the respective dose groups. For example, the overall mean daily intake was 0.173 and 0.273 mg/kg/day in the female P, and F, generation females fed 2.5 ppm, respectively. Additionally, the mean daily intake of 17/3-estradiol of F, rats was even higher in the weeks immediately following weaning.
There is a large body of clinical and experimental evidence indicating that both physiologic and pharmacologic levels of steroidal and nonsteroidal estrogens can modulate the immune system. Receptors for 17/3-estradiol have been found to be present in mouse (Detlefsen et al, 1977) and rat spleen (Katoh, 1991) , rat thymus (Grossman et al, 1979) , rat macrophages (Gulshan et al, 1990) , human lymphoid and thymic cells (Danel et al, 1983) , human CD8 positive T lymphocytes (Stimson, 1988) , and mononuclear cells (Ranelletti et al, 1988) . Exposure of rodents to natural estrogens, such as 17/3- estradiol, or synthetic nonsteroidal estrogens, such as DES, produced atrophy of the thymus (Greenman et al, 1977) , suppression of the cell-mediated immune response (Kalland, 1982) , suppression of natural killer cell activity Kalland, 1980) , myelotoxicity , and stimulation of the reticuloendothelial system (Zaki et al., 1979) . Additionally, treatment with DES has been reported to decrease host resistance to Listeria monocytogenes, HSV 1 and 2 virus, Trichinella spiralis, encephalomyocarditis virus and streptococcus sp. Morahan et al., 1984) . In humans, there is also a correlation between increased serum estradiol levels during pregnancy or the use of hormone replacement therapy in menopause and altered lymphocyte subpopulations, decreased cellmediated immunity, or altered natural killer cell function (Mathur et al., 1979; Gabrilovac et al, 1988; Manyonda et al, 1992; Brunelli et al, 1996) . In this study, exposure of both female and male rats to 10 or 50 ppm 17/3-estradiol significantly decreased total splenic WBC counts and absolute counts of total B-and T-cells. Additionally, 50 ppm 17/3-estradiol significantly decreased the absolute counts of T h -and 7" cyt/sup cells in the males. Exposure of females to 10 or 50 ppm and males to 2.5, 10, or 50 ppm 17/3-estradiol significantly decreased the mean absolute spleen weight. However, no microscopic changes, other than a mild increase in the accumulation of yellow-brown pigment within macrophages, were observed in the spleens of female or male rats. Similar to our splenic findings, Kalland and co-workers (1978) exposed mice to DES or 17/3-estradiol and observed reduced spleen weights with normal histology. Although the splenic alterations may be due, in part, to a direct effect of 17/3-estradiol on the immune system, the significant alterations in body weights observed suggest a nonspecific immunotoxic effect. Administration of sex steroids to experimental animals can alter the synthesis and release of adrenal glucocorticoid hormones (Kitay, 1963) . Glucocorticoids are known to decrease the functional ability of immune cells through the redistribution of lymphocytes, suppression of immune activation, and direct destruction of lymphoid cells (Claman, 1972) . The observed splenic effects, however, do not appear to be due to glucocorticoids. Glucocorticoids are known to induce thymic involution and alter histology (Bellamy et al, 1966; Sobhon and Jirasattham, 1974) and neither of these were observed in this study. Flaherty and co-workers (1993) reported that exposure of rats up to 70,000 times the normal plasma level of corticosterone for 21 days did not alter spleen weight or histology, whereas the spleen was affected in 17/3-estradioltreated rats. Furthermore, studies with adrenalectomized and ovariectomized animals indicate that estrogen-induced immunosuppression is not indirectly mediated through corticosteroids or alterations in hypothalamic-pituitary control (Sobhon and Jirasattham, 1974; Luster et al, 1984) . The 17/3-estradiolinduced decrease in spleen weight and cell number, as well as decreases in other organ weights, however, may be attributed to an adjustment in regulated body weight (Heywood and Wadsworth, 1980; Coling and Herberg, 1982; Hart, 1990) . Additionally, similar decreases in body and spleen weights have been observed in studies of diet restricted animals (Keenan et al, 1994) .
In studies conducted by Harris and co-workers (1974) , Sprague-Dawley rats were fed diets containing 0, 0.25, 0.62, or 1.25 ppm estradiol benzoate (EB). Rats fed 0.25 ppm EB had a reduced mating index and reduced litter size; however, at 
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Days on Test FIG. 7 . Effect of 17/3-estradiol on body weights of male (A) and female (B) rats of the F, generation over the course of the 77-day feeding period. Mean body weights were decreased in both male and female rats fed 2.5 ppm 17/3-estradiol.
higher dietary concentrations this effect was not observed. The authors concluded that these dietary concentrations of EB did not affect reproduction. Consistent with this observation, the current study observed no effect on mating index in rats fed 0.05 or 2.5 ppm 17/3-estradiol, while no litters were produced at 10 and 50 ppm 17/3-estradiol. The absence of litters at 10 and 50 ppm 17/3-estradiol is not surprising based on the ovarian pathology and estrous cyclicity data at this concentration . Although there was no effect observed on mating index at 2.5 ppm, the litter size of these animals was significantly reduced (9.8 pups/litter at 2.5 ppm vs. 13.2 pups/ litter at 0 and 0.05 ppm). Additionally, although the mean pup weights do not appear to be affected by 17/3-estradiol (6.8, 6.5, and 6.8 g at 0, 0.05, and 2.5 ppm, respectively), when analyzed using an analysis of covariance with sex ratio and litter size as the covariants, both 17/3-estradiol-treated groups were statistically significantly reduced compared with the control. This is in contrast to the findings of Ferrando and Valette (1975) , who did not observe a decrease in mean pup weight at birth in rats fed 0.12 or 0.24 ppm DES. In their study, the mean pup weights were 5.5, 5.3, and 5.1 g in rats fed 0, 0.12, and 0.24 ppm, respectively. Although they conclude that there was no effect, this may be the result of not factoring the effect of litter size and sex ratio on pup body weight (statistical analysis was not described in their report). Alternatively, the discrepancy between their study and the current study could be explained by the difference in the number of animals used in the studies (n = 30 in the current study versus n = 9 in their study). It is noteworthy that the mild decrease in mean pup weight in the 0.05 ppm group, observed in the current study, was transient. The mean pup weight of rats in the 0.05 ppm group had recovered by postnatal day 4. Additionally, the control group had a mean gestation length which was 0.5 days longer that that of the group fed 0.05 ppm 17/3-estradiol (22.3 versus 21.8 days in the control and 0.05 ppm groups, respectively). This difference, although not statistically significant, could contribute to the difference in the pup body weight at birth. In contrast, the mean weights of F, generation rats in the 2.5 ppm group remained decreased compared to that of the control group for the entire study and the mean gestation length of rats fed 2.5 ppm 17/3-estradiol was the same as that of the control group (22.3 days). Therefore, it is difficult to conclude that the observed decrease in pup birth weight in rats fed 0.05 ppm 17/3-estradiol is adverse. Preputial separation in male rats and vaginal opening in female rats are indicators of the onset of sexual maturity. Preputial separation was delayed by approximately 8 days in male rats fed 2.5 ppm 17/3-estradiol, but was not affected by administration of 0.05 ppm 17/3-estradiol. Harris and co-workers (1974) observed a slight hastening of the onset of sexual Note. Number examined is underlined. " There were no microscopic lesions in F, male rats. maturity (vaginal patency) of the female pups of rats fed EB. In their study, control rats had a mean vaginal opening age of 39 days, whereas rats fed 0.25, 0.62, or 1.25 ppm EB had a mean vaginal opening age of 34, 27, and 27 days, respectively. In the current study, statistically significant reductions in age at vaginal opening were observed in animals fed 0.05 and 2.5 ppm. The control rats had a mean age at vaginal opening of 31-2 days, while the 17/3-estradiol-treated rats had mean age of 29.5 and 22.4 days at 0.05 and 2.5 ppm, respectively. Twenty-four of the 56 female weanlings in the 2.5 ppm 17/3-estradiol group were vaginally patent on postnatal day 21, the first day they were examined. Therefore, there is a likelihood that some of the females may have been sexually mature earlier and the overall analysis of the onset of sexual maturation is slightly conservative. Future studies using estrogenic compounds should include evaluation of female sexual maturation beginning earlier than the first day of weaning. Clearly this hastening to the onset of sexual maturation is the result of 17/3-estradiol administration. It is less clear that the 1.6 day reduction in days to vaginal opening observed in rats in the 0.05 ppm 17/3-estradiol group is compound related. The range of age at vaginal opening was 26-37, 26-35, and 21-25 days of age for rats fed 0, 0.05, and 2.5 ppm 17/3-estradiol, respectively. Unfortunately, historical control data on this endpoint are not available in this laboratory. However, data reported in the literature (Harris et al., 1974) , a personal communication (Dr. L. David Wise, Merck Pharmaceuticals), and the range of control values from the current study suggest that there is a considerable interanimal variability for the age at vaginal opening in control rats. Therefore, it is unclear if the observed 1.6-day hastening in age at vaginal opening is compound related.
The purpose of this range-finder study was to: (1) evaluate various mechanistic/ biochemical endpoints for inclusion in follow-up studies; (2) evaluate the subchronic and reproductive effects of dietary 17/3-estradiol; and (3) set dose levels for future multigeneration reproduction and combined chronic toxicity/oncogenicity studies. Of the endpoints evaluated, in-life measurements (body weight, food consumption, and food efficiency), organ weights, histopathology, ovarian morphology, estrous cyclicity , hormone concentrations , sperm counts , and developmental landmarks were the most sensitive. Surprisingly, mammary gland and uterine cell proliferation were not useful markers and would not be included in future studies. While some effects were seen at 0.05 ppm (such as decreased initial birth weight and a 1.6-day earlier onset of vaginal opening in the F, generation), it is unclear whether these are compound related; future studies will clarify this. Dietary administration of 10 and 50 ppm 17/3-estradiol produced significant toxicity and animals did not successfully reproduce, clearly the maximum tolerated dose was exceeded. Subsequent studies need to more closely examine the low end of the dose-response curve at concentrations below 10 ppm.
